Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.53 |
| ▸ | MAOB | P27338 | 2/20 | 0.50 |
| ▸ | GRM6 | O15303 | 1/20 | 0.48 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.45 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.43 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | MMP8 | P22894 | 2/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | MMP13 | P45452 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16714071 | 1.00 | CD274 (0.53) | CD274MAOBGRM6PDCD1FKBP1A | |
| SCHEMBL338033 | 1.00 | CD274 (0.53) | CD274MAOBGRM6PDCD1FKBP1A | |
| SCHEMBL27819989 | 0.88 | MAOB (0.62) | CD274MAOBGRM6FKBP1AHTT | |
| Hydrochloric Acid SCHEMBL28137849 | 0.87 | MAOB (0.61) | CD274MAOBGRM6FKBP1AHTT | |
| SCHEMBL6952436 | 0.85 | MAOB (0.46) | CD274MAOBGRM6FKBP1AHTT | |
| SCHEMBL337981 | 0.83 | MEN1 (0.53) | CD274MAOBSMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL3135310 | 0.80 | F2 (0.46) | CD274MAOBFKBP1AAGTR2MMP8 | |
| SCHEMBL3135303 | 0.80 | F2 (0.46) | CD274MAOBFKBP1AAGTR2MMP8 | |
| SCHEMBL3234426 | 0.79 | ALDH1A1 (0.43) | MAOBFKBP1AHTTNPC1RAB9A | |
| SCHEMBL2771075 | 0.79 | GRM6 (0.54) | CD274MAOBGRM6PDCD1AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6624164-B2 | Solvates and/or hydrates exhibiting affinity for the arginine-vasopressin V1b receptors or for both V1b and V1a 1a receptors. | SANOFI-SYNTHELABO (FR) | 2003-09-23 | — | — | US | disclosed |
| US-20030139413-A1 | NOVEL 1,3-DIHYDRO-2H-INDOL-2-ONE DERIVATIVES, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITION CONTAINING THEM | SANOFI-AVENTIS (FR) | 2003-07-24 | — | — | US | disclosed |
| EP-0394991-B1 | 1-Azabicyclo(3.2.0)Hept-2-Ene-2-carboxylic acid compounds | FUJISAWA PHARMACEUTICAL CO (JP) | 1994-08-17 | — | — | EP | disclosed |
| US-5102877-A | Carbapenicillin antibiotics | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-04-07 | — | — | US | disclosed |
| EP-0394991-A1 | 1-Azabicyclo(3.2.0)Hept-2-Ene-2-carboxylic acid compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1990-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139413-A1 | NOVEL 1,3-DIHYDRO-2H-INDOL-2-ONE DERIVATIVES, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITION CONTAINING THEM | AVPR2, AVPR1B, AVPR1A | CD274 3289/4885MAOB 723/4885GRM6 846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.